StockData
Keros Therapeutics, Inc. logo

Keros Therapeutics, Inc. (KROS) stock

KROSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 7/30
$11.31+1.28 (+12.76%)

Close on Nov 17, 2026Market cap $224.25MP/E –Yield –

Keros Therapeutics price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

Keros Therapeutics's price to sales ratio was 13.0× on Nov 11, 2026, against 2.9× a year earlier. Over the last 3 years it ranged from 0.9× to 460.6×, with a median of 7.2×.

Price to Sales Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 202613.0×+9.6
2025Dec 31, 20253.4×−59.8
2022Apr 29, 202263.2×−397.4
2021Jan 29, 2021460.6×+236.5
2020Oct 30, 2020224.2×–

More Keros Therapeutics figures

See a number that looks wrong?